- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03362281
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
December 4, 2017 updated by: Livzon Pharmaceutical Group Inc.
Efficacy and Safety of Intravenous IIaprazole for Peptic Ulcer Bleeding: A Randomized, Double-Blind, Omeprazole-Controlled, Multicenter, and Phase 3 Trail in China
The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding.
Patients with endoscopically diagnosed peptic ulcer bleeding were enrolled in a multi-center, stratified randomized, non-inferiority test, double-blind, parallel and positive-controlled trial.
They were randomly assigned into two groups, ilaprazole and omeprazole, to be treated for up to 30 days.
The primary endpoint was the hemostasis rate at the end of 72 hours.
Secondary end points include ulcer staging changes within 72 hours, effective rate of hemostasis, hemostasis duration, average blood transfusion and rebleeding rate, etc.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients with endoscopically diagnosed gastric and duodenal ulcer bleeding were randomly assigned into two groups, ilaprazole and omeprazole.
360 patients were administrated 10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
Other 180 patients were administrated 40 mg omeprazole twice daily (at day 1-3) through intravenous infusion for 30min.
Since 4th day, both group taken oral ilaprazole tablets 10mg each day till 30th day; And the Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks.
The efficacy of ilaprazole and omeprazole was evaluated by the primary endpointthe-hemostasis rate at the end of 72 hours in the total population, high-risk groups and low-risk groups and secondary end points including ulcer staging changes within 72 hours, effective rate of hemostasis, hemostasis duration, average blood transfusion, the need to switch to other treatments (endoscopic treatment or surgery, etc.), the disappearance time of ulcer pain and rebleeding rate.
This phase Ⅲ clinical trial was designed to confirm the efficacy and safety of ilaprazole in the treatment of peptic ulcer bleeding and to pride a basis for registration.
Study Type
Interventional
Enrollment (Actual)
540
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- were 18-70 years of age, male or female.
- had symptoms of hematemesis, hematochezia, melena within 24 hours and clinically diagnosed as peptic ulcer bleeding.
- had endoscopically diagnosed gastric or duodenal ulcer bleeding and 3mm ≤ ulcer diameter ≤ 15mm.
- underwent local hemostasis according to "Acute non-variceal upper gastrointestinal bleeding guidelines (2009, Hangzhou)" Forrest grading; multiple ulcers was judged by the higher level.
- voluntarily sign informed consent
Exclusion Criteria:
- had hemorrhagic shock ( systolic blood pressure<90mmHg) or require surgery.
- were non-ulcer bleeding and gastric ulcer biopsy proved malignant.
- had gastrectomy and gastrointestinal anastomosis.
- were suffering from serious heart, liver, brain, lung, kidney and other serious diseases.
- had coagulation disorders (laboratory tests showed that platelets <80 × 109 / L, PT abnormal and exceed the normal control for 3 seconds, APTT than the normal control for 10 seconds).
- had hypersensitivity or idiosyncratic reaction to ilaprazole, omeprazole, esomeprazole or any other benzimidazole.
- had positive result of urine pregnancy test.
- used the same kind of drugs within 48 hours before entering the group.
- need to continue the combination of the following drugs that have an effect on treatment during the study: NSAIDs, corticosteroids, heparin, warfarin and vitamin K, platelet antagonists or other hemostatic agents.
- participated in a clinical trial with an investigational drug or device within the past three months.
- had alcoholic intemperance, drug addiction or other factors that researchers think it unfit for drug clinical trials.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ilaprazole
|
10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
|
Active Comparator: omeprazole
|
Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the rate of hemostasis
Time Frame: 72 hours
|
the hemostasis rate checked by endoscopy within 72 hours
|
72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2014
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
November 28, 2017
First Submitted That Met QC Criteria
December 3, 2017
First Posted (Actual)
December 5, 2017
Study Record Updates
Last Update Posted (Actual)
December 6, 2017
Last Update Submitted That Met QC Criteria
December 4, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Duodenal Diseases
- Gastrointestinal Hemorrhage
- Ulcer
- Hemorrhage
- Peptic Ulcer
- Peptic Ulcer Hemorrhage
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Amoxicillin
- Clarithromycin
- Omeprazole
Other Study ID Numbers
- Livzon-IYI-Ⅲ
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peptic Ulcer Hemorrhage
-
Uayporn KaosombatwattanaCompleted
-
Kaohsiung Veterans General Hospital.Completed
-
AstraZenecaCompleted
-
Chinese University of Hong KongNational Taiwan University Hospital; Okayama University; Tokyo University; Tsuyama... and other collaboratorsCompletedBleeding Peptic UlcerChina
-
Azienda USL ModenaRecruiting
-
National Cheng-Kung University HospitalNational Science Council, TaiwanCompleted
-
AdventHealthCompletedPeptic Ulcer Hemorrhage | Peptic Ulcer, Acute With HemorrhageUnited States
-
Kyunghee University Medical CenterCompletedActive Peptic Ulcer Disease/GI BleedingKorea, Republic of
-
Odense University HospitalRegion of Southern DenmarkUnknownBleeding Peptic UlcerDenmark
Clinical Trials on Ilaprazole
-
Il-Yang Pharm. Co., Ltd.CompletedNon-erosive Reflux DiseaseKorea, Republic of
-
Yonsei UniversityCompletedGastrointestinal Subepithelial TumorsKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.CompletedHelicobacter InfectionsKorea, Republic of
-
Livzon Pharmaceutical Group Inc.Completed
-
Il-Yang Pharm. Co., Ltd.Not yet recruitingPeptic UlcerKorea, Republic of
-
Livzon Pharmaceutical Group Inc.Completed
-
Il-Yang Pharm. Co., Ltd.CompletedGastric CancerKorea, Republic of
-
Livzon Pharmaceutical Group Inc.UnknownGastroesophageal Reflux Disease
-
Livzon Pharmaceutical Group Inc.Fifth Affiliated Hospital, Sun Yat-Sen UniversityCompletedHelicobacter Pylori Eradication Antibiotic
-
Il-Yang Pharm. Co., Ltd.CompletedHealthy | Pharmacokinetics | Pharmacodynamics | IlaprazoleCanada